Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor.

Lingerfelt MA, Zhao P, Sharir HP, Hurst DP, Reggio PH, Abood ME.

Biochemistry. 2017 Jan 24;56(3):473-486. doi: 10.1021/acs.biochem.6b01013. Epub 2017 Jan 11.

2.

Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones.

Meza-AviƱa ME, Lingerfelt MA, Console-Bram LM, Gamage TF, Sharir H, Gettys KE, Hurst DP, Kotsikorou E, Shore DM, Caron MG, Rao N, Barak LS, Abood ME, Reggio PH, Croatt MP.

Bioorg Med Chem Lett. 2016 Apr 1;26(7):1827-1830. doi: 10.1016/j.bmcl.2016.02.030. Epub 2016 Feb 16.

3.

Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands.

Kotsikorou E, Sharir H, Shore DM, Hurst DP, Lynch DL, Madrigal KE, Heynen-Genel S, Milan LB, Chung TD, Seltzman HH, Bai Y, Caron MG, Barak LS, Croatt MP, Abood ME, Reggio PH.

Biochemistry. 2013 Dec 31;52(52):9456-69. doi: 10.1021/bi4008885. Epub 2013 Dec 17.

4.

The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.

Sharir H, Console-Bram L, Mundy C, Popoff SN, Kapur A, Abood ME.

J Neuroimmune Pharmacol. 2012 Dec;7(4):856-65. doi: 10.1007/s11481-012-9351-6. Epub 2012 Mar 28.

5.

Screening for Selective Ligands for GPR55 - Antagonists.

Heynen-Genel S, Dahl R, Shi S, Milan L, Hariharan S, Sergienko E, Hedrick M, Dad S, Stonich D, Su Y, Vicchiarelli M, Mangravita-Novo A, Smith LH, Chung TDY, Sharir H, Caron MG, Barak LS, Abood ME.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Oct 30 [updated 2011 May 26].

6.

Screening for Selective Ligands for GPR55 - Agonists.

Heynen-Genel S, Dahl R, Shi S, Milan L, Hariharan S, Bravo Y, Sergienko E, Hedrick M, Dad S, Stonich D, Su Y, Vicchiarelli M, Mangravita-Novo A, Smith LH, Chung TDY, Sharir H, Barak LS, Abood ME.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Sep 29 [updated 2011 May 26].

7.

Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands.

Kotsikorou E, Madrigal KE, Hurst DP, Sharir H, Lynch DL, Heynen-Genel S, Milan LB, Chung TD, Seltzman HH, Bai Y, Caron MG, Barak L, Abood ME, Reggio PH.

Biochemistry. 2011 Jun 28;50(25):5633-47. doi: 10.1021/bi200010k. Epub 2011 Jun 1.

8.

Pharmacological characterization of GPR55, a putative cannabinoid receptor.

Sharir H, Abood ME.

Pharmacol Ther. 2010 Jun;126(3):301-13. doi: 10.1016/j.pharmthera.2010.02.004. Epub 2010 Mar 16. Review.

9.

Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.

Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME.

J Biol Chem. 2009 Oct 23;284(43):29817-27. doi: 10.1074/jbc.M109.050187. Epub 2009 Sep 1.

Supplemental Content

Loading ...
Support Center